文献速递头颈与中枢神经肿瘤

RANO 2.0:成人高级别与低级别胶质瘤神经肿瘤学疗效评估标准的更新

RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
PubMed 文献 · J Clin Oncol · 2023-09-29

RANO 2.0 基于既往研究数据更新了高级别与低级别胶质瘤的疗效评估标准,推荐所有试验采用统一标准;新诊断场景以放疗后 MRI 而非术后 MRI 为基线,放疗后 12 周内需确认进展,原发性测量仍为二维最大截面积,IDH 野生型胶质母细胞瘤除抗血管生成治疗外不再评估非强化病变。

要点

  • 推荐所有试验采用统一 RANO 2.0 标准,无论治疗方式。
  • 新诊断场景以放疗后 MRI 为基线,放疗后 12 周内进展需重复 MRI 或组织病理学确认。
  • IDH 野生型胶质母细胞瘤除抗血管生成治疗外不再评估非强化病变。

核心结论

  • 修订后的 RANO 2.0 标准完善了胶质瘤的疗效评估。

研究设计与样本

  • 基于评估不同标准的既往研究数据,提出 RANO 2.0 更新。

主要发现

  • 推荐高级别与低级别胶质瘤采用统一标准,用于所有试验,无论所评估的治疗方式。
  • 新诊断场景以放疗后 MRI 而非术后 MRI 作为与后续扫描比较的基线。
  • 放疗后 12 周内假性进展发生率高,需继续治疗并重复 MRI 确认进展或组织病理学证据明确复发肿瘤方可定义肿瘤进展。
  • 该期间之后或复发肿瘤治疗评估中,确认扫描非强制;对假性进展可能性高的治疗,强烈推荐重复 MRI 强制确认进展。
  • 主要测量仍为肿瘤最大截面积(二维),体积测量为可选;IDH 野生型胶质母细胞瘤除抗血管生成治疗评估外不再评估非强化病变;IDH 突变肿瘤伴显著非强化成分时,临床试验可要求同时评估强化和非强化肿瘤成分。

关键数值与推荐

  • 推荐所有试验采用统一 RANO 2.0 标准,无论治疗方式。
  • 新诊断场景以放疗后 MRI 为基线。
  • 放疗后 12 周内进展需重复 MRI 确认或组织病理学证据。
  • 对假性进展可能性高的治疗,强烈推荐重复 MRI 强制确认进展。
  • 主要测量为二维最大截面积,体积测量为可选。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. METHODS: Informed by data from studies evaluating the different criteria, updates to the RANO criteria are proposed (RANO 2.0). RESULTS: We recommend a standard set of criteria for both high- and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the postradiotherapy magnetic resonance imaging (MRI), rather than the postsurgical MRI, will be used as the baseline for comparison with subsequent scans. Since the incidence of pseudoprogression is high in the 12 weeks after radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, are required to define tumor progression. However, confirmation scans are not mandatory after this period nor for the evaluation of treatment for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (two-dimensional) but volumetric measurements are an option. For IDH wild-type glioblastoma, the nonenhancing disease will no longer be evaluated except when assessing response to antiangiogenic agents. In IDH-mutated tumors with a significant nonenhancing component, clinical trials may require evaluating both the enhancing and nonenhancing tumor components for response assessment. CONCLUSION: The revised RANO 2.0 criteria refine response assessment in gliomas.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wen PY, van den Bent M, Youssef G, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol. 2023. PMID: 37774317. doi:10.1200/JCO.23.01059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。